Aratana Therapeutics Inc (PETX)

6.59
NASDAQ : Health Care
Prev Close 6.59
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.15 / 10.73
Avg Volume 500.70K
Exchange NASDAQ
Shares Outstanding 37.04M
Market Cap 240.79M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

PETX LOSS NOTICE: Rosen Law Firm Reminds Aratana Therapeutics, Inc. Investors Of Important Deadline In Class Action - PETX

PETX LOSS NOTICE: Rosen Law Firm Reminds Aratana Therapeutics, Inc. Investors Of Important Deadline In Class Action - PETX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aratana Therapeutics, Inc securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the "Class Period") of the important April...

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

PETX INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm

PETX INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aratana Therapeutics, Inc.

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Aratana Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Aratana Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC announces that it is investigating Aratana Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Aratana Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Aratana Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc securities (NASDAQ: PETX) from March 16, 2015 through February 3, 2017,...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Aratana Therapeutics, Inc. - PETX

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Aratana Therapeutics, Inc. - PETX

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Aratana Therapeutics, Inc.

Stocks Sink as Investors Digest President Trump's Moves

Stocks Sink as Investors Digest President Trump's Moves

Stocks close out Monday lower as uncertainty over potential policy moves from Donald Trump's administration continue to weigh on Wall Street.

Stocks Trade Lower, Energy Sector Leads Decliners

Stocks Trade Lower, Energy Sector Leads Decliners

Stocks fall Monday as uncertainty over potential policy moves from Donald Trump's administration weigh on Wall Street.

Shark Bites: If You're Not in the Right Stocks, You're in Trouble

Shark Bites: If You're Not in the Right Stocks, You're in Trouble

Market is showing a lack of interest today.

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

Aratana Therapeutics To Attend North American Veterinary Conference

Aratana Therapeutics To Attend North American Veterinary Conference

Provides Update on Availability of ENTYCE® (capromorelin oral solution)

Trading Action Has Improved, Here's What I Am Playing

Trading Action Has Improved, Here's What I Am Playing

Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.

It's an Actual Pullback for a Change

It's an Actual Pullback for a Change

This morning the most notable aspect of the action is the complete failure to bounce so far.

We Hit Dow 20K, Now What?

We Hit Dow 20K, Now What?

How to play the market now that the DJIA has finally crossed 20,000.

So We Hit Dow 20K, Now What?

So We Hit Dow 20K, Now What?

Keep in mind that moves like this create underlying support.

Galliprant® (grapiprant Tablets) Now Available For Canine Osteoarthritis

Galliprant® (grapiprant Tablets) Now Available For Canine Osteoarthritis

Elanco launches first-in-class piprant for veterinary use

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Stock Picks Are Hard to Find as Small-Caps Struggle

Stock Picks Are Hard to Find as Small-Caps Struggle

With poor breadth and money managers hiding in large-caps, I am being cautious, right now.

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Trying to Knock Out Some Individual Trades, but it Is not Easy

Trying to Knock Out Some Individual Trades, but it Is not Easy

If the indices take out yesterday's lows I'll be very bearish very quickly.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Market Sees Rise in Performance Anxiety

Market Sees Rise in Performance Anxiety

I've got my eye on steel and biotechnology names to put cash to work.